跳至主要内容
临床试验/EUCTR2015-000736-15-DE
EUCTR2015-000736-15-DE进行中(未招募)1 期

Additive Effect of Twice Daily Brinzolamide 1% /Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to a Prostaglandin Analogue - Simbrinza BID as an Adjunctive to Prostaglandin Analogue (PGA)

Alcon Research, Ltd.0 个研究点目标入组 280 人开始时间: 2015年7月24日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
280

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Diagnosed with either open-angle glaucoma or ocular hypertension.
  • 2. Must sign an informed consent form.
  • 3. Willing and able to attend all study visits.
  • 4. Other protcol-specified inclusion criteria may apply
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 140
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 140

排除标准

  • 1. Women of childbearing potential who are pregnant, breastfeeding, intend to become pregnant during the study, or not using adequate birth
  • control methods to prevent pregnancy throughout the study
  • 2. Any form of glaucoma other than open-angle glucoma or ocular hypertension
  • 3. Ocular disease, trauma, infection, inflammation, pathology, or surgery as specified in the protocol
  • 4. Any other conditions including severe illness which would make the subject, in the opinion of the Investigator, unsuitable for the study
  • 5. Other protocol-specified exlcusion criteria may apply

研究者

相似试验